Who Should Get ‘Fat Jabs’ Like Ozempic & Wegovy? The Weight-Loss Drug Debate
As governments grapple with soaring obesity-related healthcare costs—now exceeding $1.2 trillion annually in the U.S. Alone—semaglutide-based weight-loss medications like Wegovy (FDA-approved in 2021) and tirzepatide (Zepbound, approved in 2024) have ... Read More